[Edaily Reporter NA EUN-KYUNG ] #Ingenia Therapeutics (950260) remains confident in the development of its new glaucoma drug despite Merck (MSD) of the U.S. deciding not to exercise its option. This is because other major global pharmaceutical companies have expressed interest and reached out to the company since MSD decided not to exercise its option on the glaucoma treatment candidate “IGT-302.”
Ingenia plans to pursue a technology export deal after demonstrating the candidate’s value in clinical trials. The company aims to differentiate the drug by restoring the structure and function of the aqueous humor outflow pathways—unlike existing eye drops—and to develop it as a long-acting treatment administered once every three months.
On the 18th, an Ingenia official stated, “After news broke that MSD had not exercised its option, other major global pharmaceutical companies have approached us expressing interest in IGT-302,” adding, “We plan to demonstrate its efficacy in clinical trials and discuss technology licensing with various global pharmaceutical companies.”
Han Sang-yeol, CEO of Ingenia Therapeutics. (Photo: Ingenia Therapeutics)
“We aim to replace daily eye drops with an injection administered every three months”
IGT-302
,
developed by Ingenia
,
is a novel antibody drug that lowers intraocular pressure by restoring the structure and function of the “Schlem’s canal,” the passageway through which aqueous humor—the fluid inside the eye—drains. By directly activating TIE2, a protein receptor that maintains the structure and function of blood vessels, the drug normalizes the drainage pathway itself, and is expected to provide a long-lasting reduction in intraocular pressure. Based on this mechanism, Ingenia is developing a long-acting treatment administered once every three months.
Han Sang-yeol, CEO of Ingenia, said in a recent interview with E-Daily, “We are developing IGT-302 with the goal of a dosing schedule of one intraocular injection per quarter,” adding, “We aim to provide patients with more stable therapeutic efficacy and convenience in terms of both the duration of effect and the frequency of administration.”
Nonclinical trials confirmed that intraocular pressure decreased within a few days of administration and that the effect persisted for more than one month. CEO Han explained, “Results from experiments conducted on primates and human eyes showed that intraocular pressure decreased within a few days of administration, and the effect was observed to last for more than a month.” Ingenia plans to verify whether the targeted three-month dosing interval can be achieved in future clinical trials.
Glaucoma is a disease in which the optic nerve is damaged, leading to a gradual narrowing of the visual field. In the early stages, there are no noticeable symptoms, and central vision is maintained for a relatively long time; as a result, by the time patients notice something is wrong, the disease is often already quite advanced. Since there is no way to restore a damaged optic nerve, missing the window for treatment can lead to blindness.
According to a study published in the international journal *Ophthalmology*, the number of glaucoma patients worldwide is projected to increase from approximately 76 million in 2020 to about 111.8 million in 2040. The number of patients receiving treatment in South Korea has also risen from approximately 1.08 million in 2021 to about 1.27 million in 2025. Global market research firm Global Market Insights forecasts that the glaucoma treatment market will grow from $6.6 billion (approximately 9 trillion won) in 2024 to $10.5 billion (approximately 14 trillion won) in 2034.
Current standard treatment for glaucoma focuses on lowering intraocular pressure to slow the progression of optic nerve damage. Patients use eye drops daily to inhibit aqueous humor production or promote its drainage; if intraocular pressure is not adequately controlled, they may combine multiple medications or undergo laser or surgical treatment.
Treatments designed to reduce the long-term burden of medication are also emerging. The U.S. Food and Drug Administration (FDA) approved AbbVie’s “Durista” in 2020 and Glaucose’s “iDose TR” in 2023. Both products are implantable formulations that gradually release existing intraocular pressure-lowering medications. Unlike these drugs, which extend the release period, Ingenia aims to restore the function of the aqueous humor drainage pathway itself.
Schematic diagram of the mechanism of action for Ingenia Therapeutics’ new glaucoma drug candidate, “IGT-302.” Unlike existing treatments, it aims to lower intraocular pressure and inhibit the progression of optic nerve damage by normalizing the structure and function of the Schlemm’s canal, the aqueous humor outflow pathway. (Source: Ingenia Therapeutics)
A different mechanism from competing drugs that stalled in Phase 2… Also targeting normal-tension glaucoma
Global glaucoma drug development primarily focuses on enhancing the intraocular pressure-lowering effects of existing drugs or improving the convenience of administration. “NCX 470,” developed by France’s Nicox, is an eye drop that combines the nitric oxide-releasing function with existing prostaglandin-class drugs; it has completed Phase 3 clinical trials and entered the U.S. approval process. In South Korea, Kukje Pharma(002720)and Huons Co., Ltd.(243070)are developing improved glaucoma drugs in Phase 3 clinical trials by combining existing ingredients or improving formulations.
Of course, there have also been attempts to develop new drugs aimed at restoring the function of aqueous humor outflow channels, such as Ingenia. A prime example is “Rajuprotapib” (AKB-9778), developed by U.S.-based AirPio Pharmaceuticals. This compound indirectly activates the TIE2 receptor by blocking VE-PTP, a protein that inhibits TIE2 receptor activity. However, although additional intraocular pressure-lowering effects were observed in Phase 2 clinical trials when used in combination with existing eye drops, the magnitude of the effect was insufficient, and the trial did not proceed to Phase 3.
In contrast, Ingenia’s IGT-302 differs in that it is a novel antibody drug that directly activates the TIE2 receptor. Ingenia expects this mechanism of action to result in higher target selectivity and differentiated efficacy compared to existing competitive drugs.
CEO Han stated, “There have been several research papers indicating that lazuprotapib indirectly activates not only TIE2 but also various other receptors, including VEGFR2,” adding, “The limitations of this drug’s mechanism of action are known to be one of the reasons why further late-stage clinical development was not possible.”
Another therapeutic area of interest for Ingenia is normal-tension glaucoma. Approximately 70–80% of glaucoma patients in Korea have normal-tension glaucoma, a condition in which optic nerve damage progresses despite intraocular pressure (IOP) remaining within the normal range. While existing treatments that further lower IOP are effective for these patients, a problem remains: some patients continue to experience optic nerve damage even after IOP has been sufficiently reduced.
Ingenia is focusing on the potential of IGT-302 to not only lower intraocular pressure by restoring the function of the Schlemm’s canal but also to improve blood flow in the retinal vessels and protect the optic nerve. If this effect is proven, it could become a new treatment option for patients whose disease progression could not be halted with existing therapies.
CEO Han stated, “We hypothesize that, in addition to reducing intraocular pressure by restoring the Schlemm’s canal, IGT-302 will also normalize retinal blood vessels to increase blood flow, thereby indirectly contributing to optic nerve protection,” adding, “We intend to validate this hypothesis in late-stage clinical trials.” However, its efficacy for normal-tension glaucoma has not yet been verified in non-human primate studies.
Ingenia also cited the clinical results of “IGT-427,” a candidate drug for age-related macular degeneration currently under development by MSD, as a basis for its confidence in the development of IGT-302. While both compounds directly activate the TIE2 receptor, IGT-427 is a bispecific antibody that also inhibits vascular endothelial growth factor (VEGF).
CEO Han stated, “Although the trials were conducted independently, a comparison of the 12-week clinical trial results for IGT-427 with those of existing VEGF inhibitors at the 12-week mark reveals that IGT-427 demonstrates faster and superior clinical efficacy compared to standard treatments,” adding, “We believe this difference proves the clinical utility of TIE2 activation.”
Since IGT-427 also possesses VEGF-inhibitory properties and the comparison was made between results from different trials, these clinical outcomes cannot be directly attributed to the efficacy of IGT-302. However, they can serve as evidence supporting the clinical potential of the TIE2 activation mechanism. Based on this, Ingenia plans to continue the development of IGT-302.
Ingenia is currently conducting the nonclinical studies required for the Investigational New Drug (IND) application for IGT-302. The company plans to initiate its own Phase 1/2a clinical trial in 2027 and complete it in 2028, after which it intends to pursue technology transfer based on the clinical data obtained.
CEO Han emphasized, “IGT-302 directly activates TIE2 and does not act on other targets, giving it a highly selective and very clean mechanism of action,” adding, “The duration of action is also very satisfactory, and we expect it to be sufficiently competitive in the market.”
InBody Co., Ltd.(041830)reported that its operating profit for the third quarter of this year nearly doubled year-over-year; however, its recurring operating profit—excluding one-time accounting effec…
GS Retail(007070)has supported domestic small and medium-sized partner companies in Vietnam in expanding their overseas sales channels, resulting in export consultation deals totaling approximately $1…
Boil-like lumps repeatedly form and burst in areas such as the armpits and groin. Pus, oozing, and pain persist, and if the condition worsens, drainage tracts (channels connecting lesions beneath the …